El interés en corto de Portage Biotech da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Portage Biotech. Los datos de interés en corto se actualizan cada dos semanas.

Portage Biotech (NASDAQ:PRTG) Bolsa, Informe de interés en corto

Portage Biotech

Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.

Earnings

News

Markets

Trading Ideas

APDN

AUID

CERO

COMM

CRVS

EFSH

FSBW

NIVF

NUKK

PRTG

PRZO

PTPI

RZLV

SHLT

SSBK

TNXP

VSTE

Acciones de Corvus suben un 22,5% pre-market tras anunciar datos de Soquelitinib. Descubre más ganadores y perdedores.

Acciones de Corvus Pharmaceuticals (CRVS) suben alrededor del 22%; 20 acciones que se mueven en premercado

Portage Biotech Inc

Wells Fargo analyst Eric Luebchow initiates coverage on Smartstop Self Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMA#NYSE">SMA</a>) with a Overweight rating and announces Price Target of $38.

Price Target

Initiation

Analyst Ratings

Wells Fargo Initiates Coverage On Smartstop Self Storage with Overweight Rating, Announces Price Target of $38

Truist Securities analyst David Macdonald reiterates Encompass Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EHC#NYSE">EHC</a>) with a Buy and raises the price target from $116 to $135.

Reiteration

Truist Securities Reiterates Buy on Encompass Health, Raises Price Target to $135

NAAS

NaaS Technology Shares Halted On Circuit Breaker To The Upside, Shares Up 9.16%

Truist Securities analyst Youssef Squali upgrades Peloton Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTON#NASDAQ">PTON</a>) from Hold to Buy and maintains the price target from $11 to $11.

Upgrades

PTON

Truist Securities Upgrades Peloton Interactive to Buy, Maintains Price Target to $11

Wedbush analyst Michael Pachter reiterates FuboTV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUBO#NYSE">FUBO</a>) with a Outperform and maintains $6.4 price target.

FUBO

Wedbush Reiterates Outperform on FuboTV, Maintains $6.4 Price Target

Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors. Agree Realty, LCI Industries, and Allete have rewarded shareholders for years and recently announced dividend increases. These companies currently offer dividend yields of up to nearly 6%.
Agree Realty
Agree Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADC#NYSE">ADC</a>) is a real estate investment trust that acquires and develops properties net leased to industry-leading, omnichannel retail tenants.
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
</ul>
Agree Realty has increased its dividends consecutively for the last 12 years. In its most recent dividend announcement on April 10, it raised the monthly payout from $0.253 to $0.256 per share, equal to an annual figure of $3.072 per share. The dividend yield on the stock currently stands at 3.88%.
Agree Realty&#8217;s annual revenue as of Dec. 31 stood at $617.10 million. According to its Q1 2025 earnings release on April 22, the company posted revenues of $169.16 million and AFFO of $1.06. Both figures came in above the consensus estimates.&nbsp;
If you invested $10,000 in Agree Realty stock 10 years ago, how much would you have now? Check out this <a href="https://www.benzinga.com/real-estate/25/04/44604608/if-you-invested-10k-in-agree-realty-stock-10-years-ago-how-much-would-you-have-now">article by Benzinga</a> to learn more.&nbsp;
Trending: The secret weapon in billionaire investor portfolios that you almost certainly don't own yet. <a href="https://www.benzinga.com/money/masterworks">See which asset class has outpaced the S&amp;P 500 (1995-2024) – and with near-zero correlation.</a>
LCI Industries
LCI Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LCII#NYSE">LCII</a>) manufactures and supplies engineered components for the manufacturers of recreational vehicles and adjacent industries in the U.S. and internationally.
LCI Industries has increased dividends every year for the last nine years. According to its most recent dividend hike announcement on Nov. 14, 2024, the company's board raised the quarterly payout from $1.05 to $1.15 per share, equal to an annual figure of $4.60 per share. More recently, in its dividend announcement on Feb. 19, the company maintained the payout at the same level. The current dividend yield on the stock is 5.83%.
The company&#8217;s annual revenue as of Dec. 31 stood at $3.74 billion. In its Q4 2024 earnings release on Feb. 11, it posted revenues of $803.14 million and EPS of $0.37, both above the consensus estimates.
See Also: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.
Allete
Allete (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALE#NYSE">ALE</a>) operates as an energy company in two segments, Regulated Operations and Allete Clean Energy. It generates electricity from coal-fired, biomass co-fired/natural gas, hydro, wind, and solar.
The company has raised its dividends every year for the last 14 years. As per its most recent dividend hike announcement on Jan. 30, its board increased the quarterly payout by 3.5% to $0.73, equaling an annual figure of $2.92 per share. The current dividend yield is 4.48%.
ALLETE&#8217;s annual revenue as of Dec. 31 stood at $1.53 billion. In its most recent earnings report on Feb. 13, the company posted Q4 2024 revenues of $364.80 million and EPS of $0.87. Both figures missed consensus estimates.
Agree Realty, LCI Industries, and Allete are good choices for investors seeking reliable passive income. Their dividend yields of up to nearly 6% and long history of consistent hikes make them attractive to income-focused investors.
Check out this <a href="https://www.benzinga.com/personal-finance/25/04/44940859/why-johnson-johnson-chevron-and-flowers-foods-are-winners-for-passive-income">article by Benzinga</a> for three more stocks offering high dividend yields.&nbsp;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>
Image: Shutterstock

Personal Finance

LCII

Why  Agree Realty, LCI Industries, And Allete Are Winners For Passive Income

Loop Capital analyst Alan Gould maintains Charter Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) with a Hold and raises the price target from $385 to $430.

CHTR

Loop Capital Maintains Hold on Charter Communications, Raises Price Target to $430

Truist Securities analyst Ki Bin Kim initiates coverage on Smartstop Self Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMA#NYSE">SMA</a>) with a Buy rating and announces Price Target of $38.

Truist Securities Initiates Coverage On Smartstop Self Storage with Buy Rating, Announces Price Target of $38

Wedbush analyst Alicia Reese reiterates Cinemark Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNK#NYSE">CNK</a>) with a Neutral and maintains $32 price target.

Wedbush Reiterates Neutral on Cinemark Holdings, Maintains $32 Price Target

Loop Capital analyst Garik Shmois maintains MasterBrand (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MBC#NYSE">MBC</a>) with a Buy and lowers the price target from $19 to $16.

Citigroup Financial 300% Minupon Princ Protected Nts for Russell 2000 Index

Loop Capital Maintains Buy on MasterBrand, Lowers Price Target to $16

Treasury Secretary Scott Bessent&nbsp;has called on China to take proactive steps towards easing trade tensions while expressing optimism over trade deals with other countries. 
What Happened: Bessent pointed out China&#8217;s higher export rate to the U.S. as a key factor contributing to the current tariff imbalance while speaking to <a href="https://www.cnbc.com/2025/04/28/treasury-secretary-bessent-says-its-up-to-china-to-de-escalate-trade-tensions.html">CNBC</a>. &#8220;They sell five times more to us that we sell to them,&#8221; stated the Treasury Secretary. He also termed the trade relations with China &#8220;complicated.&#8221;
Bessent also shed light on the progress of U.S. trade negotiations, hinting at a potential deal with India. "I would guess that India would be one of the first trade deals we would sign. So watch this space," stated Bessent. 
The Treasury Secretary is also hopeful of trade deals with other countries, including Japan. "We've had many countries come forward and present some very good proposals, and we're evaluating those," he said.
He pointed out that the euro has strengthened against the U.S. dollar since trade tensions began, indicating that European countries are likely worried about the situation.
SEE ALSO:&nbsp;<a href="https://benzinga.com/news/25/04/45029504/elon-musks-ex-wives-missed-out-on-his-billion-dollar-wealth-heres-why" target="_blank" rel="noreferrer noopener">Elon Musk&#8217;s Ex-Wives Missed Out on His Billion-Dollar Wealth — Here&#8217;s Why</a>
Why It Matters: Bessent&#8217;s call for de-escalation comes amidst a series of significant developments in the global trade sphere. China has denied any ongoing trade talks with the U.S., but it has reportedly begun <a href="https://www.benzinga.com/news/global/25/04/45004954/china-reportedly-begins-exempting-key-us-imports-from-tariffs-including-pharma-and-aerospace-parts">exempting </a>some U.S. imports from high tariffs, indicating a possible easing of trade tensions. This move could potentially pave the way for further negotiations and a more balanced trade relationship between the two nations.
Meanwhile, Vice President JD Vance, last week, announced <a href="https://www.benzinga.com/25/04/44919025/jd-vance-finalizes-terms-for-trade-deal-with-indian-prime-minister-modi-trump-wants-america-and-india-to-grow">finalized </a>terms for a trade deal with India, aiming to double bilateral trade to $500 billion by the end of the decade. This deal is expected to focus on job creation, resilient supply chains, and prosperity for workers in both nations.
The developments come in the wake of President Donald Trump&#8216;s recent global duties announcement, which has stirred uncertainty in the markets. Despite this, Trump has opted to maintain a 10% tariff across the board, while delaying harsher levies against individual trading partners for 90 days.
Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) declined 7.26%, while the SPDR S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) lost 5.69% on a year-to-date basis, amid tariff uncertainties. 
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/news/25/04/45028145/joe-rogan-agrees-with-bernie-sanders-saying-hes-right-that-you-should-be-scared-of-oligarchs-they-shouldnt-b" target="_blank" rel="noreferrer noopener">Joe Rogan Agrees With Bernie Sanders, Saying &#8216;He&#8217;s Right That You Should Be Scared Of Oligarchs; They Shouldn&#8217;t Be Running The Government&#8217;</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Treasury Secretary Scott Bessent Says It's Up To China To 'De-Escalate' Trade Tensions, India To Be The 'First Trade Deal' To Be Signed

Macro Economic Events

Global

Economics

INDA

Watching Shares Of Stocks In The South Asian Subregion; Reuters Exclusively Reports, Pakistan Defence Minister Says Military Incursion By India Is Imminent; Pakistan Defence Minister Says Pakistan's Military Presence Has Been Reinforced On Border With India; Pakistan Defence Minister Says In A Normal Armed Conflict, Both Countries Should Refrain From Using Nuclear Option

Loop Capital analyst Garik Shmois maintains American Woodmark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMWD#NASDAQ">AMWD</a>) with a Buy and lowers the price target from $100 to $75.

AMWD

Loop Capital Maintains Buy on American Woodmark, Lowers Price Target to $75

Since bottoming during its Sankhya move in 2009, the S&amp;P 500 has rallied sharply—up nearly 795% from that low and 173% since the beginning of its C4 phase in the Adhishthana Cakra Cycle. Most recently, the index formed the Nirvana level at 5097.855 after completing the 24th weekly bar of its C6 phase. This level now acts as a significant anchor and will guide price behavior over the next twelve phases.
<figure class="wp-block-image aligncenter size-full is-resized"><img loading="lazy" decoding="async" width="854" height="658" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26061222/SP-C6-Highlighted.png" alt="S&amp;P 500 Nirvana Level" class="wp-image-11669" style="width:400px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26061222/SP-C6-Highlighted.png 854w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26061222/SP-C6-Highlighted-300x231.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26061222/SP-C6-Highlighted-768x592.png 768w" sizes="(max-width: 854px) 100vw, 854px" /><figcaption class="wp-element-caption">S&amp;P 500 Nirvana Level (Shaded: C6 Phase)</figcaption></figure>
For instance, if the index climbs another 3,000 to 4,000 points and is met with a black swan event, the Nirvana level (5097.855) will act as a magnetic pullback zone, just as it did on the 25th bar of C6, when concerns over tariffs and the global trade war triggered a sharp decline. That drop found support exactly at the Nirvana level, from where buying quickly resumed.&nbsp;
<figure class="wp-block-image aligncenter size-full is-resized"><img loading="lazy" decoding="async" width="1200" height="754" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26061334/SP-500-Channel.png" alt="S&amp;P 500 Monthly Channel" class="wp-image-11670" style="width:454px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26061334/SP-500-Channel.png 1200w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26061334/SP-500-Channel-300x189.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26061334/SP-500-Channel-1024x643.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26061334/SP-500-Channel-768x483.png 768w" sizes="(max-width: 1200px) 100vw, 1200px" /><figcaption class="wp-element-caption">S&amp;P 500 Monthly Channel</figcaption></figure>
Technically, the index remains within a well-defined bullish channel.
Yet through the lens of Adhishthana Principles, two structural concerns stand out:
<ul>
<li>The index did not form the Yajna pattern in C3</li>
<li>It did not test the Renunciation level in C5 </li>
</ul>
<figure class="wp-block-image aligncenter size-full is-resized"><img loading="lazy" decoding="async" width="626" height="420" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26061457/SP-500-No-Yajna-Formation.png" alt="S&amp;P 500 No Yajna Formed" class="wp-image-11672" style="width:450px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26061457/SP-500-No-Yajna-Formation.png 626w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26061457/SP-500-No-Yajna-Formation-300x201.png 300w" sizes="(max-width: 626px) 100vw, 626px" /><figcaption class="wp-element-caption">S&amp;P 500: Absence of Yajna Formation</figcaption></figure>
<figure class="wp-block-image aligncenter size-full is-resized"><img loading="lazy" decoding="async" width="660" height="638" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26061630/Sp-500-No-renunciation-1.png" alt="S&amp;P 500 Level of Renunciation" class="wp-image-11673" style="width:383px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26061630/Sp-500-No-renunciation-1.png 660w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26061630/Sp-500-No-renunciation-1-300x290.png 300w" sizes="(max-width: 660px) 100vw, 660px" /><figcaption class="wp-element-caption">S&amp;P 500: Level of Renunciation Not Tested</figcaption></figure>
These missing elements create a latent imbalance in the cycle. Although momentum and structure remain positive in the near term, this incomplete alignment suggests the potential for a strong Fall of Artah and Artharthi—a set of two significant corrective moves—beginning around 1 March 2027. Given the steep chart structure, if triggered, this could fracture the current Cakra Cycle and set the stage for the more severe Move of Pralay.
Although the trend remains constructive for now, with a higher-high, higher-low formation intact, long-term portfolio structuring, hedge positioning, and large sell-side block execution should factor in the C7 phase decline beginning in March 2027 and extending into mid-2028. This holds particular relevance for institutional investors, macro strategists, and block trade desks managing long-duration exposure.
While the surface suggests strength, the underlying structure is less certain. The S&amp;P 500 continues its ascent—graceful and soaring—but, like a kite, it dances in a hurricane.&nbsp;
Disclaimer: The above analysis is based on the Adhishthana Principles, a proprietary market theory I developed to interpret cyclical and structural patterns in financial markets.

Broad U.S. Equity ETFs

Technicals

Opinion

Signals

S&P 500: A Kite Dancing In A Hurricane

Loop Capital analyst Rob Sanderson maintains Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Buy and lowers the price target from $900 to $695.

Loop Capital Maintains Buy on Meta Platforms, Lowers Price Target to $695

<ul>
<li>TSLA</li>
<li>NVDA</li>
<li>GLD</li>
<li>BULL</li>
<li>WOLF</li>
<li>AAPL</li>
<li>$BTC</li>
<li>HOOD</li>
<li>GOOGL</li>
<li>MAGA</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

$BTC

AAPL

BULL

GOOGL

HOOD

MAGA

NVDA

TSLA

WOLF

Top 10 Trending Stocks On WallStreetBets As Of April 28, 2025 (Via Swaggy Stocks)

The Safari Collection is a world-renowned luxury safari company and owner of the Giraffe Manor
This is another leading safari company in Africa that has placed an order with Tembo
The first order was from Asilia Africa announced in February 2025
Tembo's solutions selected to drive sustainable safari experiences across Kenya
LONDON, April 28, 2025 (GLOBE NEWSWIRE) -- VivoPower International PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVPR#NASDAQ">VVPR</a>, the "Company"))) is pleased to announce that its wholly-owned subsidiary, Tembo e-LV, has secured an inaugural order for its EV conversion kits from The Safari Collection, owner of luxury properties in Kenya, including the Giraffe Manor, Sasaab, Sala's Camp and Solio Lodge.

VVPR

Vivopower Subsidiary Tembo e-LV Secures Order For EV Conversion Kits From The Safari Collection

On April 28, 2025, Medicus Pharma Ltd. (the "Company") issued a press release announcing that the Company entered into a binding letter of intent, dated April 26, 2025 (the "Letter Agreement"), pursuant to which the Company has agreed to acquire all of the issued and outstanding shares of Antev Ltd. ("Antev") on a share exchange basis (the "Transaction"). Antev is a clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as first in market product for cardiovascular high-risk prostate cancer patients and patients with first acute urinary retention (AURr) episodes due to enlarged prostate. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.
Subject to certain assumptions, qualifications and conditions, the Company will negotiate and enter into a definitive agreement with Antev to acquire all issued and outstanding Antev shares, on a fully-diluted basis, in exchange for 2,666,600 common shares of the Company ("Consideration Shares"), representing approximately 19% of the issued and outstanding common shares of the Company as of the date of the Letter Agreement. In addition to resale restrictions prescribed under applicable securities laws, the Consideration Shares will be subject to a 9-month staggered lock-up release and an agreement granting certain voting rights in favor of Company management for a period of 36 months.
Upon the achievement of certain milestones related to potential future U.S. Food and Drug Administration ("FDA") Phase 2 and New Drug Administration approvals, Antev shareholders will be entitled to receive up to approximately US$65 million in additional contingent consideration.

MDCX

Medicus Pharma To Acquire Antev Ltd. For 19% Equity Stake, Or ~2.67M Shares, With Potential $65M In Milestone Payments For Prostate Drug Teverelix

Barclays analyst Brandon Oglenski maintains Saia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) with a Overweight and lowers the price target from $475 to $290.

SAIA

Barclays Maintains Overweight on Saia, Lowers Price Target to $290

Susquehanna analyst Charles Minervino maintains Schlumberger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) with a Positive and lowers the price target from $48 to $46.

Susquehanna Maintains Positive on Schlumberger, Lowers Price Target to $46

Press Releases

Portage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024

Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter

Portage Biotech Announces Letter of Intent with Immunova for an Option to Acquire iOx Therapeutics, Ltd

Management

General

Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company

Financing

Portage Biotech Announces Completion of $2.15 Million Private Financing

Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements

Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial

Health Care

Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7

Emerging Tech Quartet – PRSO, LXRX, PRTG, RNAZ – Drive Breakthroughs Across Defense, Obesity, Oncology, and RNA Therapeutics

Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7

LXRX

PRSO

RNAZ

ABVC BioPharma

BioVie

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

Equillium

Ernexa Therapeutics

Evaxion Biotech A/S - American Depositary Share

Evaxion Biotech

Geovax Labs

Imunon

IN8bio

Kairos Pharma

Moleculin Biotech

MEI Pharma

Marker Therapeutics

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

NextCure

BiomX

Polyrizon

Rallybio

Synlogic

Cantor Fitzgerald

Oppenheimer

WIIM

Portage Biotech shares are trading higher after the company reported confirmatory preclinical efficacy data for PORT-7.

Comments

Portage Biotech

Interés en corto

Portage Biotech (NASDAQ:PRTG) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL